Datalec Precision Installations Appoints Peter Cole as Executive Vice President for APAC Region
Datalec Precision Installations (DPI), a provider of world-class data centre design, supply, build, and managed services delivering seamless and integrated end-to-end solutions for data centre operators, today announced the appointment of Peter Cole as Executive Vice President for the Asia-Pacific (APAC) region. Based in Singapore, Cole will spearhead DPI's expansion and strategic growth initiatives across APAC's dynamic data centre market, expected to nearly double to $150.59 billion by 2029.
Bringing over four decades of experience in the electrotechnical and digital industry, Cole brings a wealth of expertise to his new role. He will oversee all aspects of DPI's APAC data centre business, including strategic planning, operations, and business development.
"Peter's extensive experience and deep understanding of the APAC market make him the ideal leader to drive our growth in this critical region," said Danny Keeper, Group Director of DPI. "His proven track record in delivering large-scale, complex projects and building high-performing teams aligns perfectly with our commitment to operational excellence and innovation."
Cole's appointment comes at a crucial juncture as DPI aims to strengthen its position in the rapidly expanding digital infrastructure landscape, with reports of a compound annual growth rate (CAGR) of 23.60 percent by 2033. His leadership will be instrumental in meeting the increasing demand for data centre capacity driven by cloud computing, AI, and digital transformation initiatives.
"I am pleased to take on this exciting opportunity to lead DPI's data centre business in the APAC region," said Cole. "With the demand for digital infrastructure growing exponentially, this is a pivotal time for the industry. I look forward to leveraging my experience and collaborating with our talented teams and partners to deliver innovative and sustainable solutions that will shape the future of data centres in the APAC region."
Throughout his career, Cole has demonstrated a strong commitment to sustainability, quality, and safety in data centre operations. As Executive Vice President, Cole will be crucial in setting and executing regional growth strategies, managing key client relationships, and optimising operational efficiency. He will work closely with DPI's global headquarters in Hertfordshire, UK, to ensure alignment with the company's overall objectives and to drive sustainable growth and profitability in the APAC market.
Learn more about Datalec Precision Installations (DPI): https://datalecltd.com
About Datalec
Datalec Precision Installations provides world-class data centre design, build, and installation services that leverage unique technical expertise, including technical and critical cleaning, electronic security, and managed services. Our 'One Call, One Team' service ensures a seamless end-to-end solution, achieving the highest levels of performance and efficiency. DPI's rigorous project management benefits customers by minimising risks and reducing costs. In addition, our proactive and flexible approach guarantees the delivery of customised solutions that exceed customer requirements. For more information, visit: https://datalecltd.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001848222/en/
Contacts
Media Contact
Ilissa Miller
iMiller Public Relations
Email: datalec@imillerpr.com
Tel: 1.914.315.6424
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cybersecurity Teams Can’t Keep up With Growing Levels of Cyberattacks, New Research Reveals1.10.2024 14:00:00 EEST | Press release
Cybersecurity teams are under strain, as 61% of European cybersecurity professionals say that their organisation’s cybersecurity team is understaffed, and over half (52%) believe that their organisation’s cybersecurity budget is underfunded. That’s according to new research from ISACA, the leading global professional association helping individuals and organisations in their pursuit of digital trust. Staff and funding struggles are having an impact on wellbeing as 68% feel that their role is more stressful now compared to five years ago, with 79% putting this down to the increasingly complex threat landscape. Two in five (41%) of respondents say they are experiencing more cyberattacks when compared to a year ago, and 29% think they are experiencing the same amount. But respondents don’t feel the number of attacks will be slowing down any time soon. Over half (58%) state it is likely their organisation will experience a cyberattack in the next year. This has increased by 6 percentage po
New Pharmanovia Study Results Reveal Chloral Hydrate Noticeably Improves Severe Insomnia Within Two Weeks1.10.2024 13:45:00 EEST | Press release
FOR MEDICINAL TRADE AND BUSINESS MEDIA ONLY Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises the lifecycle of established medicines, today announced positive topline results of its open label RESTORE trial in severe insomnia, in partnership with Lindus Health. A topline readout using patient-reported outcomes (PROs) has found that short-term use of chloral hydrate shows benefit in people with severe insomnia where it is interfering with normal daily life and when other therapies (behavioural and pharmacologic) have failed. The trial (NCT06053840) enrolled 100 adult patients who received chloral hydrate treatment over 14 days and came from primary and secondary care sites. Patients were closely monitored by a virtual team of secondary care sleep specialists, as part of the decentralised trial design, and were assessed for the safety, tolerability and identification of baseline characteristics, changes in sleep and quality of life outcomes.
RSA and Swissbit Announce New Phishing-Resistant Authentication Solution for Security-First Industries1.10.2024 12:00:00 EEST | Press release
RSA, the security-first identity leader and Swissbit, a long-standing leading expert and manufacturer of storage, security, and embedded IoT solutions, announced a new, next-generation hardware authenticator series today designed to protect highly regulated industries. The RSA iShield Key 2 series, powered by Swissbit, will provide financial services, energy, healthcare, and other highly regulated organizations with the highest-level of phishing-resistant, passwordless authentication needed to simplify credential management and drive toward Zero Architecture (ZTA). Optimized for the RSA cloud identity and access management (IAM) platform, RSA® ID Plus, the RSA iShield Key 2 series offers premiere security and unparalleled flexibility. The RSA iShield Key 2 series is available for order now and will ship Q4 2024. “The worst attacks demand the best defenses. That’s why security-first leaders have trusted RSA for decades to defend them from the most damaging cyberattacks. By working with
TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal1.10.2024 11:46:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech focused on using its proprietary GMP compliant technology platform, C-Stem™, to develop life-saving cell therapies, today published an article in Neurotherapeutics, demonstrating the first successful bioproduction of a Parkinson’s Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009598667/en/ TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics) The potential of cell therapy for Parkinson’s Disease is well documented – dating back to pioneering studies in the 1980s using fetal cell transplants – and scientific progress over the last decades provides great hope for the future. The emergence of induced pluripotent cells (iPSCs) opened new pathways and solved one of the first ma
Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells1.10.2024 11:30:00 EEST | Press release
AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid tumors and lymphomas. This development program builds on AOP Health’s proven success in delivering cancer stem cell targeting agents that address patients’ unmet medical needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241001468319/en/ AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart) Focus on a promising target The new compound, AOP208, targets and blocks a protein on the surface of the cancer stem cell, the serotonin receptor 1B, which may prove to be critical to treat the root cause of the disease. The compound is given orally and was designed and initially
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom